Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.

The advance makes it easier to detect circulating tumor DNA in blood samples, which could enable earlier cancer diagnosis and help guide treatment.

In addition to turning on genes involved in cell defense, the STING protein also acts as an ion channel, allowing it to control a wide variety of immune responses.

The new strategy may enable engineered T cells to eradicate solid tumors such as glioblastoma.

By applying a language model to protein-drug interactions, researchers can quickly screen large libraries of potential drug compounds.

The targeted approach eliminated tumors in mice, with minimal side effects.

The potent new adjuvant could be used to help make vaccines against HIV and other infectious diseases.

Boosting the efficiency of single-cell RNA-sequencing helps reveal subtle differences between healthy and dysfunctional cells.

With computer models and lab experiments, researchers are working on a strategy for vaccines that could protect against any influenza virus.

In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells.